Acinetobacter baumannii has emerged as an important nosocomial pathogen. The mechanisms of drug resistance acquisition in a. Acinetobacter baumannii is an opportunistic pathogen that poses an increasing threat in the healthcare community. Infections caused by multidrugresistant acinetobacter baumannii have emerged as a serious problem throughout the world. An array with six oligonucleotide probes based on the 16s23s rrna gene intergenic spacer its region was developed to differentiate species in the a. A team of australian and portuguese investigators has discovered yet another resistance mechanism in the pathogen, acinetobacter baumannii, in this. First report of colistin resistance among carbapenem. The current study investigated the emergence of colistin resistance among carbapenemresistant strains of a.
Methods strains and growth conditions the study included 27 nonduplicate multidrugresistant a. Treatment is complicated by multidrugresistance mdr. It involved identification of clinically recovered a. Acinetobacter is nonmotile, obligate aerobic gramnegative coccobacillus and are ubiquitous freeliving saprophytes in soil and water. Pdf prevalence of multidrug resistant acinetobacter baumannii in. The global emergence of multidrug resistant acinetobacter baumannii has reduced the number of clinically available antibiotics that retain activity against this pathogen. The patterns indicate various strains of multidrugresistant acinetobacter baumannii mdrab as defined by pulsedfield gel electrophoresis. The purpose of this study was to evaluate the prevalence, biotyping, and antibiotic resistance status of a. Multidrug resistant acinetobacter baumannii inside and outside hospital setting.
After the outbreak was halted in late october, the number of cases of mdrab remained somewhat elevated in november because of an. Its ability to survive in a hospital milieu and its ability to persist for extended periods of time on surfaces makes it a frequent cause for healthcareassociated infections and it has led to multiple outbreaks. Mortality rates associated with multidrugresistant. Melamed r, greenberg d, porat n, karplus m, zmora e, golan a, et al. Prevalence of multidrugresistant acinetobacter baumannii. Epidemiological characteristics and drug resistance. New resistance mechanism in the often multidrug resistant. Acinetobacter baumannii in intensive care units icus are increasing ji ye et al. Multidrugresistant acinetobacter baumannii mdrab was found in the environment of 48 percent of the rooms of patients colonized or infected with the pathogen, according to a new study.
A total of 5,058 patients cultured positive with a. Colistin is one of the promising options for treatment of multidrugresistant a. Among all gramnegative bacteria, acinetobacter baumannii is an emerging pathogen that accounts for about 80% of all reported infections. In order to better understand transmission and evolutionary dynamics of mdr acinetobacter baumannii ab during longterm infection, we analyzed genomes from a series of isolates from individual. Limited treatment options are available for patients infected with multidrug mdr or pandrug pdrresistant bacterial pathogens, resulting in infections that can persist for weeks or months. Multidrugresistant acinetobacter baumannii, a major hospitalacquired pathogen, is a serious health threat and poses a great challenge to healthcare providers. Bacteremia due to acinetobacter baumannii complex abc, which composed of four genomic species gen. This strain spread rapidly and caused a large outbreak in the hospital. Appropriate selection of antibiotics for the treatment of the majority of severe microbial infections. Acinetobacter baumannii complex abc has emerged as an important pathogen causing a variety of infections. In february 2006, a patient colonized with a multidrugresistant sequence type 56 acinetobacter baumannii strain was admitted to a hospital in madrid, spain. Studies have demonstrated that fosfomycin is a promising drug, particularly in combination with other.
Antibioticresistant acinetobacter baumannii increasing success. A 5year surveillance study on antimicrobial resistance of. The risk factors and spread of multidrugresistant acinetobacter baumannii in intubated patients in a medical intensive care unit aim. Current hospital cleaning protocol may be inadequate to rid patient rooms of multidrugresistant mdr acinetobacter baumannii, according to a. Longitudinal multicenter surveillance data on abc from different sources in taiwan have not been published. Emergence of extensively drugresistant acinetobacter. Between june 1, 2004, and march 14, 2005, 16 patients in the surgicalmedical intensive care unit icu were infected and another 2 were colonized with multidrugresistant mdr acinetobacter baumannii. Acinetobacter baumannii has been reported increasingly as a. The purpose of this study is to determine the risk factors for mrab in a city hospital patient population. Research article control of an outbreak of acinetobacter. Isolation and identification of multidrug resistant. Acinetobacter baumannii has been reported increasingly as a significant. We investigated 118 patients, on 27 wards, in whom mdr a. Pdf acinetobacter baumannii, a nonmotile, glucose non.
Journal of infection and public health 20 6, 179185 prevalence of multidrugresistant acinetobacter baumannii and pseudomonas aeruginosa in an italian hospital m. Acinetobacter baumannii can cause severe infections, mainly in critically ill inpatients. Acinetobacter baumannii, a gramnegative opportunistic pathogen in humans. The aim of this study was to determine the incidence and mortality of this multiresistant strain of acinetobacter in patients undergoing cardiac surgery, to elucidate the effectiveness of treatment with colistin and to.
Manca1 institute of microbiology, university of brescia, italy. Antimicrobial susceptibility of acinetobacter baumannii isolated from hospital patients. Investigation of the infection control approach against. Multidrugresistant acinetobacter baumannii found growing. Multidrug resistant acinetobacter baumannii, mrab is an important cause of hospital acquired infection. Control of hospital endemicity of multipledrugresistant. Among them, acinetobacter baumannii, a ubiquitous, strictly aerobic, nonfermentative coccobacillus, has emerged. Therefore, it is considered as a new threat in hospitals, which requires a. A retrospective analysis of carbapenemresistant acinetobacter. An outbreak of multidrugresistant acinetobacter baumannii. To understand the epidemiology of multidrugresistant mdr acinetobacter baumannii and define individual risk factors for mdr, we used epidemiologic methods, performed organism typing by pulsedfield gel electrophoresis pfge, and conducted a matched casecontrol retrospective study. Multidrugresistant acinetobacter baumannii medscape.
Healthcare provider information sheet for acinetobacter. The spread of multidrugresistant acinetobacter baumannii mdra has become a global concern, but detection of mdra is comparatively rare in japan. Since the 1970s, the spread of multidrugresistant mdr acinetobacter strains among critically ill, hospitalized patients, and subsequent epidemics, have become an. Old antibiotics, such as fosfomycin and polymyxins, are now considered potential treatment alternatives to overcome the lack of new antibiotics 24. Successful control of an acinetobacter baumannii outbreak in a neonatal intensive care unit. It is difficult to control, and the infections caused by it are difficult to treat, because it is multidrug resistant. An increasing endemicity of multipledrugresistant acinetobacter baumannii mrab st457 was noted in hong kong. In germany, to date, little is known on the extent of mdr in a. The outbreak period was in september and october 2003, when a marked increase in the number of cases was noted. This retrospective study was conducted to determine the prevalence and antibiotic resistance pattern of a.
Multidrugresistant acinetobacter baumannii volume 11. Acinetobacter baumannii has emerged over the last decade as a significant opportunistic pathogen and primarily associated with hospitalacquired infections. Characteristics of multidrugresistant acinetobacter. For this reason, the development of novel treatment strategies for infections. Prevalence of multidrug resistant acinetobacter baumannii. Although other species of acinetobacter are also often associated with hais.
Oligonucleotide arraybased identification of species in. Emergence of extensivelyresistant acinetobacter baumannii. Pdf acinetobacter baumannii, most often multidrug resistant, is a difficult to treat pathogen particularly in intensive care units icus of a. The aim of this study was to determine the prevalence and increasing antibiotic resistance of a. The acinetobacter species cause infections, which are associated with increased morbidity and mortality rates 4. Although there have been many genomic studies on the evolution and antibiotic resistance of this species, there have been very limited transcriptome studies on its responses to antibiotics.
The drugresistant nature of the pathogen and its unusual and. Introduction the extensive use of antibiotics and the gradual increase of different types of drugs have made bacteria resistant to drugs 1,2. Analysis of tigecycline resistance development in clinical. However, the presence of mdra was confirmed in our hospital, after isolation from the sputum of a patient who had received treatment for cerebral infarction at a hospital in a neighboring country, and then was admitted to our hospital after. While there are many species of acinetobacter that can cause human disease, acinetobacter baumannii a. Gramnegative bacilli including multidrugresistant acinetobacter baumannii mdrab are responsible for severe icuacquired infections, mainly pneumonia and bacteraemia. The incidence of multidrugresistant acinetobacter baumannii mdr a. Acinetobacter baumannii has proven to be an increasingly important and demanding species in health careassociated infections. Epidemiology of mrab survival in the environmental conditions, including seawater especially in the warm period of the year up to 50 days, may also. Ijerph free fulltext infection control programs and. Management of multidrugresistant acinetobacter spp. Since the 1970s, the spread of multidrugresistant mdr acinetobacter strains among critically ill, hospitalized patients, and subsequent epidemics, have become an increasing cause of concern. Acinetobacter baumannii is the most common nosocomial pathogen among all acinetobacter spp. Multidrugresistant acinetobacter baumannii infection following paraarticular steroid injection in the knee.
We describe the systematic investigation initiated to discover an environmental reservoir and a novel measure taken to terminate the outbreak. Multidrugresistant acinetobacter baumannii is an important bacterium causing nosocomial infections. Treatment of acinetobacter infections oxford academic. Multidrug resistant acinetobacter baumannii isolates from. Acinetobacter baumannii, a strictly aerobic, nonfermentative, gramnegative coccobacillary rodshaped bacterium, is an opportunistic pathogen in humans. Research multidrugresistant acinetobacter baumannii. Acinetobacter baumannii is an important cause of nosocomial infections worldwide.
This protective effect was significant after confounding. Multidrug resistant acinetobacter baumannii in veterinary. The epidemiology, risk factors, and infection control measures to prevent nosocomial transmission of this epidemic clone were analyzed. The aim of this study was to determine the risk factors for colonization in the. Acinetobacter baumannii is one of the most common causes of ventilatorassociated pneumonia in intensive care units.
Most of the isolates were obtained from rectal swabs of. Acinetobacter is a gramnegative bacterium commonly found in soil and water. Genome dynamics of multidrugresistant acinetobacter. Acinetobacter baumannii, most often multidrug resistant, is a difficult to treat pathogen particularly in intensive care units icus of a hospital. Prevalence and resistance profile of acinetobacter. Abstract acinetobacter baumannii is an emerging gramnegative nosocomial pathogen that rarely causes infections in or. Analysis of the extracellular proteome of colistin. Complete genome of the multidrugresistant acinetobacter. Clinical manifestations, antimicrobial therapy, and prognostic factors. The epidemiology of multidrugresistant acinetobacter baumannii. The administration of penicillin had a protective effect against isolation of mdr a. The challenges of treating multidrugresistant bacteria continue to be at the forefront of the clinicians practice in caring for hospitalized patients. Antimicrobial susceptibility of acinetobacter baumannii.
1071 220 1512 679 42 523 417 318 1132 830 1414 1280 1327 298 1185 510 1264 263 483 1444 213 489 1446 49 339 1010 1387 1007 231 1274 277 1490 739 1463 1022 556 1174 1247 945 136 919 1294 1058 1097 543 1398 759 827